A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)

Project: Research

StatusActive
Effective start/end date6/11/195/11/24

Keywords

  • clinical trial
  • phase 3 study
  • treatment efficacy
  • Prostate cancer